You are correct - that one is based on current revenue. But I do have one based on future revenue, on the assumption that they successfully expand into Asia and/or Europe and continue to build in USA, increasing operating margins etc.. His forward looking valuation for that was $1.00 - $1.50. But could be way higher if it's more aggressive on the assumptions. Obviously sentiment and market conditions will be a factor as well.
I can find out the methodology, leave it with me.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-476
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.010(4.55%) |
Mkt cap ! $48.10M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.0¢ | $87.21K | 406.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 400685 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 23537 | 2 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |